High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

In a large-scale diagnostic study, artificial intelligence (AI) assistance led to a superior improvement in prostate cancer detection on MRI, increasing diagnostic accuracy by 3.3% compared with ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

Targeting men in the top 10% of genetic risk helped detect high-grade prostate cancer that conventional screening would miss, paving the way for more personalized and effective early detection ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Recent advances in prostate cancer awareness have transformed how the disease is detected and treated. New screening tools, including AI-enhanced MRI and urine-based biomarker tests, are catching ...

A trial found no meaningful difference in detection of clinically significantly prostate cancer between multiparametric MRI-based and microultrasound-based biopsy techniques.

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...